Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03245554|
Recruitment Status : Not yet recruiting
First Posted : August 10, 2017
Last Update Posted : April 9, 2018
|Condition or disease||Intervention/treatment||Phase|
|Gastrointestinal Cancer||Drug: Propranolol||Early Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||80 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Research on Teratment of Gastrointestinal Cancer in the Preoperative by Propranolol|
|Estimated Study Start Date :||May 1, 2018|
|Estimated Primary Completion Date :||September 1, 2020|
|Estimated Study Completion Date :||September 1, 2020|
Experimental: placebo and propranolol
We used propranolol and placebo as an control drug to treat with patients.
0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
Other Name: placebo
- Tumor size will be measured. [ Time Frame: Our experiment completed after patients took medicine for one week. ]We used CT and Ki67 to confirm that the drug's affection.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03245554
|Contact: Yijing Hefirstname.lastname@example.org|
|Institute of Clinical Pharmacology|
|Changsha, Hunan, China, 410005|